<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139743">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02155582</url>
  </required_header>
  <id_info>
    <org_study_id>16790</org_study_id>
    <secondary_id>2013-004746-42</secondary_id>
    <nct_id>NCT02155582</nct_id>
  </id_info>
  <brief_title>Copanlisib Pharmacodynamic Study</brief_title>
  <official_title>A Phase I Pharmacodynamic Study of Copanlisib (BAY 80-6946) as Monotherapy in Patients With Non-Hodgkin's Lymphoma and Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to analyze what the study drug does to the body and its relationship to drug
      levels and safety after patients with advanced cancer have been treated with copanlisib in
      different dose groups.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Maximum change from baseline in expression of pathway inhibition (pAKT) in surrogate tissue (platelet rich plasma) during copanlisib monotherapy</measure>
    <time_frame>Baseline and approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum change from baseline in plasma glucose during 2 cycles of copanlisib monotherapy</measure>
    <time_frame>Baseline and after day 22</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC(0-168) of copanlisib after each copanlisib IV infusion during 2 cycles of copanlisib monotherapy</measure>
    <time_frame>After day 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs as characterized by type, frequency, severity (as graded by CTCAE) and relationship to study drug</measure>
    <time_frame>Approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum change from baseline in insulin during 2 cycles of copanlisib</measure>
    <time_frame>After day 22</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum change from baseline in C-peptide during 2 cycles of copanlisib</measure>
    <time_frame>After day 22</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FDG PET early response (decreased SUVmax compared to baseline) after dosing with copanlisib for non-diabetic patients with detectable FDG tumor uptake at baseline</measure>
    <time_frame>After day 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in expression and / or phosphorylation of PI3K pathway proteins in paired tumor biopsies</measure>
    <time_frame>Baseline and after day 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non Hodgkin Lymphoma (NHL)</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 mg and 60 mg for the diabetic patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copanlisib (BAY80-6946)</intervention_name>
    <description>0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients;45 mg and 60 mg for the diabetic patients; Intravenous (IV) infusion over 1 hour. Dosing of copanlisib will be on Days 1, 8, and 15 of each 28 day treatment cycle.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of the following NHL:  follicular lymphoma all
             grades, lymphoplasmacytic lymphoma / Waldenström macroglobulinemia, transformed
             indolent lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, mantle cell
             lymphoma, or peripheral T-cell lymphoma, relapsed or refractory, with 1 or more prior
             chemo-immunotherapy- or immunotherapy-based regimen(s)

        OR

          -  Advanced and / or refractory solid tumors with high likelihood of PI3K pathway
             activation (e.g. breast and endometrial cancers)

          -  Biopsy-accessible tumor

          -  Male or female patients equal 18 or more years of age

          -  NHL patients must have at least 1 bi-dimensionally measurable lesion according to the
             modified Cheson criteria.  Patients with solid tumors must have at least 1 solid
             tumor lesion measurable by computed tomography or magnetic resonance imaging
             according to the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST
             1.1) criteria

          -  Eastern Cooperative Oncology Group performance status 2 or &lt;

          -  Life expectancy of at least 3 months

          -  Adequate bone marrow, liver, and renal functions as assessed by laboratory
             requirements conducted within 7 days before the first dose of study drug

          -  Left ventricular ejection fraction &gt; or equal the lower limit of normal for the
             institution

        Exclusion Criteria:

          -  Previous or concurrent cancer that is distinct in primary site or histology from NHL
             or the solid tumor, for which the patient is enrolled into this study, within 5 years
             before treatment start EXCEPT for curatively treated cervical cancer in situ,
             non-melanoma skin cancer, in situ breast cancer, in situ prostate carcinoma if
             Gleason score &lt; or equal to 6 and prostate-specific antigen &lt;10 ng/mL, and
             superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1
             (tumor invades lamina propria)]

          -  Known lymphomatous involvement of the brain or leptomeningeal involvement; solid
             tumor patients with central nervous system (CNS) metastases if treatment completed &lt;3
             months before enrollment or lesions unstable or progressing on magnetic resonance
             imaging scans performed within 1 month of enrollment or unstable symptoms of the CNS
             metastases

          -  Any illness or medical condition that is unstable or could jeopardize the safety of
             the patient or his / her compliance in the study

          -  Current diagnosis of type 1 or type 2 diabetes mellitus with HbA1c &lt; or equal to 8.5%
             or fasting blood glucose &lt; or equal to 160 mg/dL
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayerhealthcare.com</email>
  </overall_contact>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>June 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumors</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
